DEC 02, 2016 7:50 AM PST

Aspirin-Like Drug Prevents Progression of Head and Neck Cancer

WRITTEN BY: Kara Marker
People suffering from head and neck cancer can be treated through surgery, chemotherapy, and radiation, but a typical prognosis following treatment still isn’t very bright. Even when patients successfully receive these treatments, they only have a 50-50 chance of living more than five years.
Prostaglandin.
In search of a more effective and long-lasting treatment, scientists are jumping on the cancer immunotherapy bandwagon. This technique of boosting the immune system has worked for other types of cancer, and now researchers from the Medical University of South Carolina and the Ralph H. Johnson VA Medical Center are seeking the same result for head and neck squamous cell carcinoma (HNSCC) patients. Although, senior author M. Rita Young, PhD, said that head and neck cancers are “notorious” for evading the immune system’s efforts to naturally eliminate tumor cells.

Young’s research prior to the present study showed that the composition of immune cells within premalignant lesions differs from that within progressed versions of HNSCC. During the transition from premalignant to malignant, Young found, the immune environment changed from inflammatory to immunosuppressive, preventing the immune cells from having any deleterious effect on the cancer cells. Young thought that a lipid mediator called prostaglandin might play a key role in the transitioning immune environments, and that idea led to her reaching the findings presented in her latest study.

Researchers used a mouse model of HNSCC to observe the impact on tumor progression while inhibiting prostaglandin. Treating premalignant lesions with a non-steroidal anti-inflammatory drug (NSAID), indomethacin, successfully inhibited prostaglandin. Then, the researchers saw a massive increase in immune cell presence, stimulation of the entire immune system, and a reduction in tumor burden on the body.

"If we can be more persistent and focused on finding premalignant lesions before they become malignant, simple therapies might be beneficial," explained postdoctoral fellow and co-author, Sara Johnson, PhD.

Specifically, inhibiting prostaglandin production with indomethacin led to an increase in Th1-associated cytokines - IL-2 and IFN-y - and Th2-associated cytokines, like IL-10. Cytokines like interleukins (ILs) and interferon (IFN) are chemical messengers used by the immune system to communicate under certain states of disease. In a given situation, the presence of certain cytokines indicate to scientists what response the immune system is attempting to produce.
M. Rita Young, Ph.D. Source: Medical University of South Carolina
Turning these findings into realistic action to prevent premalignant lesions from developing into cancer is Young’s next mission. First, she’ll have to confirm that inhibiting prostaglandin in humans yields the same results as in the mouse models of HNSCC. Then she’ll have to find the best candidate drug for inhibiting prostaglandin and boosting the immune system.

Young said, "Immunotherapy should be considered as a treatment strategy for premalignant lesions before they progress to cancer. We can detect them. Why not treat them?"

Young’s study was recently published in the journal Frontiers in Immunology.
 


Source: Medical University of South Carolina
Prostaglandin image: National Center for Biotechnology Information. PubChem Compound Database; CID=5280360
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
SEP 27, 2019
Immunology
SEP 27, 2019
Diseases We Share with Our Canine Companions: Autoimmune Encephalitis in Dogs
Like humans, dogs can develop autoimmune encephalitis, and it’s common - mostly affecting smaller breeds and young adult dogs. Now scientists underst...
OCT 25, 2019
Drug Discovery & Development
OCT 25, 2019
Novel Therapeutic For Eradicating The Flu Virus
Public Health officials have long warned about pandemic pathogens flying fast around the world. One virus already spreads across the globe annually leading...
DEC 04, 2019
Neuroscience
DEC 04, 2019
Antibiotic Usage May Cause Parkinson's, Study Finds
A study from Helsinki University Hospital, Finland suggests that excessive usage of certain antibiotics may increase one’s risk of developing Parkins...
DEC 16, 2019
Drug Discovery & Development
DEC 16, 2019
Vaccine To Protect Against The Zika Virus
Scientists at The University of Texas Medical Branch at Galveston present for the first time how a single high dose vaccine can protect a pregnant mouse al...
JAN 08, 2020
Cell & Molecular Biology
JAN 08, 2020
In a First, Scientists Generate Early Human Immune Cells in the Lab
Now we know more about the early stages of the human immune system....
FEB 13, 2020
Cancer
FEB 13, 2020
Can Ebola help treat glioblastomas?
You might want to sit down for this. New research published in the Journal of Virology has named a surprising new ally to brain tumors: Ebola. Yes, yo...
Loading Comments...